Clinical Trials Page  
  L-MARC Home Page  ::  
   
 
Obesity and Adiposopathy Clinical Trials

 

EFFECT AND SAFETY OF LIRGLUTIDE 3.0 MG IN SUBJECTS WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES MELLITUS TREATED WITH BASAL INSULIN
(PRINCIPAL INVESTIGATOR, 2016)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF LONG-TERM TREATMENT WITH BELVIQ (LORCASERIN HCL) ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND CONVERSION TO TYPE 2 DIABETES MELLITUS IN OBESE AND OVERWEIGHT SUBJECTS WITH CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS
(PRINCIPAL INVESTIGATOR, 2014)

A 20 WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO ASSESS THE EFFICACY AND SAFETY OF HM11260C ON BODY WEIGHT IN OBESE SUBJECTS WITHOUT DIABETES
(PRINCIPAL INVESTIGATOR, 2014)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF THE CO-ADMINISTRATION OF CANAGLIFLOZIN 300MG AND PHENTERMINE 15 MG WITH PLACEBO FOR THE TREATMENT OF NON-DIABETIC OVERWEIGHT AND OBESE SUBJECTS
(PRINCIPAL INVESTIGATOR, 2013)

A PHASE 1, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ACCESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE IV DOSES OF PF-05231023 IN OBESE HYPERLIPIDEMIC ADULT SUBJECTS WITH AND WITHOUT TYPE 2 DIABETES MELLITUS ON A BACKGROUND OF ATORVASTATIN
(PRINCIPAL INVESTIGATOR, 2013)

A 26 WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARIOUS DOSES OF HPP404 ON WEIGHT LOSS IN OVERWEIGHT OR OBESE SUBJECTS
(PRINCIPAL INVESTIGATOR, 2012)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE OCCUREENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN OVERWEIGHT AND OBESE SUBJECTS WITH CARDIOVASCULAR RISK FACTORS RECEIVING NALTREXONE SR/BUPROPION SR
(PRINCIPAL INVESTIGATOR, 2011)

EFFECT OF LIRAGLUTIDE ON BODY WEIGHT IN OVERWEIGHT OR OBESE SUBJECTS WITH TYPE 2 DIABETES: A 56 WEEK RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE ARMED PARALLEL GROUP, MULTICENTRE, MULTINATIONAL TRIAL WITH A 12 WEEK OBSERVATIONAL FOLLOW-UP PERIOD
(PRINCIPAL INVESTIGATOR, 2011)

A 26- WEEK, RANDOMISED, CONTROLLED, OPEN LABEL, MULTICENTRE, MULTINATIONAL, TREAT TO TARGET TRIAL INVESTIGATING THE IMPACT OF DIETARY INTERVENTION ON WEIGHT CHANGE AND THE RELATIONSHIP BETWEEN WEIGHT CHANGE AND BASELINE BODY MASS INDEX (BMI) IN SUBJECTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON ORAL ANTIDIABETIC DRUGS (OADS) INITIATION INSULIN THERAPY WITH INSULIN DETEMIR IN COMBINAITON WITH METFORMIN
PRINCIPLE INVESTIGATOR (2010)

DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF 400 MG OF VELNEPERIT (S-2367) AND 120 MG OF ORLISTAT ADMINISTERED INDIVIDUALLY OR COMBINED ORALLY THREE TIMES PER DAY WITH A REDUCED CALORIE DIET (RCD) IN OBESE SUBJECTS
PRINCIPLE INVESTIGATOR (2010)

A DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, 16 WEEK STUDY OF 0, 400, OR 1600 MG/DAY S-2367 ADMINISTERED ORALLY ONCE-A-DAY WITH OR WITHOUT A LOW CALORIE DIET LEAD-IN IN OBESE MALES AND FEMALES
PRINCIPLE INVESTIGATOR (2010)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF JNJ-28431754 IN NONDIABETIC OVERWEIGHT AND OBESE SUBJECTS
PRINCIPAL INVESTIGATOR (2008)

A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, PLACEBO-CONTROLLED, EFFICACY AND SAFETY TRIAL TO EVALUATE THE EFFECT OF SCH 497079 ON WEIGHT IN OBESE AND OVERWEIGHT SUBJECTS
PRINCIPAL INVESTIGATOR (2008)

EFFECT OF LIRAGLUTIDE ON LONG-TERM WEIGHT MAINTENANCE FOLLOWING WEIGHT LOSS INDUCED BY A 12 WEEK LOW CALORIE DIET IN OBESE SUBJECTS; A 52 WEEK RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE TRIAL WITH A 12 WEEK FOLLOW-UP PERIOD.
PRINCIPAL INVESTIGATOR (2008)

DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 12-WEEK STUDY OF THE SAFETY AND EFFICACY OF ATHX-105 PHOSPHATE FOR THE TREATMENT OF OBESITY
PRINCIPAL INVESTIGATOR (2008)

A MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF MBX-8025 IN MODERATELY OBESE HYPERLIPIDEMIC PATIENTS WITH OR WITHOUT CONCOMITANT ATORVASTATIN.
PRINCIPAL INVESTIGATOR (2007) 

A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTICENTER STUDY TO DETERMINE THE SAFETY AND EFFICACY OF VI-0521 IN THE TREATMENT OF OBESITY IN ADULTS WITH OBESITY-RELATED CO-MORBID CONDITIONS
(PRINCIAL INVESTIGATOR (2007)

A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO DETERMINE THE SAFETY AND EFFICACY OF V1-0521 IN THE TREATMENT OF OBESITY IN AN ADULT POPULATION WITH BMI ≥35
PRINCIPAL INVESTIGATOR (2007)

52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF LORCASERIN HYDROCHLORIDE IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS MANAGED WITH ORAL HYPOGLYCEMIC AGENT(S) [BLOOM-DM: BEHAVIORAL MODIFICATION AND LORCASERIN FOR OVERWEIGHT AND OBESITY MANAGEMENT IN DIABETES MELLITUS.]
PRINCIPAL INVESTIGATOR (2007)

A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF LORCASERIN HYDROCHLORIDE IN OVERWEIGHT AND OBESE PATIENTS. [BLOSSOM: BEHAVIORAL MODIFICATION AND LORCASERIN SECOND STUDY FOR OBESITY MANAGEMENT]
PRINCIPAL INVESTIGATOR (2007)

A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY COMPARING THE SAFETY AND EFFICACY OF NALTREXONE 32MG SUSTAINED RELEASE (SR)/BUPROPION 360MG SUSTAINED RELEASE (SR) AND PLACEBO IN OBESE SUBJECTS WITH TYPE 2 DIABETES MELLITUS
PRINCIPAL INVESTIGATOR (2007)

A RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY TO EXAMINE THE SAFETY, TOLERABILITY, AND BODY WEIGHT EFFECT OF SUBCUTANEOUS PRAMLINTIDE ALONE AND IN COMBINATION WITH THE ORAL ANTIOBESITY AGENTS SIBUTRAMINE AND PHENTERMINE IN OVERWEIGHT AND OBESE SUBJECTS.

PRINCIPAL INVESTIGATOR (2007)

A PHASE IIB/III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-0364 IN OBESE PATIENTS AND IN OVERWEIGHT PATIENTS WITH OBESITY-RELATED CO-MORBIDITIES, FOLLOWED BY A 1-YEAR EXTENSION
PRINCIPAL INVESTIGATOR (2007)

A RANDOMIZE, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EXAMINE THE EFFECT OF BETAHISTINE ON BODY WEIGHT IN OBESE SUBJECTS
PRINCIPAL INVESTIGATOR (2006)

A DOUBLE-BLIND, RANDOMIZED, PARALLEL, EFFICACY STUDY EVALUATING LOSARTAN POTASSIUM ALONE OR IN COMBINATION WITH HYDROCHLOROTHIAZIDE VERSUS PLACEBO IN OBESE PATIENTS WITH ELEVATED SYSTOLIC AND DIASTOLIC BLOOD PRESSURE
PRINCIPAL INVESTIGATOR (2006)

A 2-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF MK-0364 IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2006)

AN 18-MONTH STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF MK-0364 IN OBESE PATIENTS.
PRINCIPAL INVESTIGATOR (2006)

BEHAVIORAL MODIFICATION AND LORCASERIN SECOND STUDY FOR OBESITY MANAGEMENT (BLOOM). A 104 WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY LORCASERIN HYDROCHLORIDE IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2006)

OPEN-LABEL EXTENSION OF INITIAL 16-WEEK PROOF-OF-CONCEPT STUDY TO CONTINUE ADMINISTRATION OF S-2367 ORALLY ONCE-A-DAY FOR 12 ADDITIONAL MONTHS (IE, 52 WEEKS) IN OBESE MALES AND FEMALES.
PRINCIPAL INVESTIGATOR (2006)

A PHASE IIB/III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-0364 IN OBESE PATIENTS AND IN OVERWEIGHT PATIENTS WITH OBESITY-RELATED CO-MORBIDITIES
PRINCIPAL INVESTIGATOR (2006)

A 2-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OBESE SUBJECTS
PRINCIPAL INVESTIGATOR (2006)

OPEN-LABEL EXTENSION OF INITIAL 16-WEEK PROOF-OF-CONCEPT STUDY TO CONTINUE ADMINISTRATION OF S-2367 ORALLY ONCE-A-DAY FOR 6 ADDITIONAL MONTHS IN OBESE MALES AND FEMALES.
PRINCIPAL INVESTIGATOR (2006)

A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO AND POSITIVE-CONTROLLED PHASE 2B STUDY TO EVALUATE THE EFFECT OF VARIOUS DOSES OF CP-945,598 ON WEIGHT LOSS IN OBESE SUBJECTS
PRINCIPAL INVESTIGATOR (2005)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF L-000328495 IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2005)

AN 18 MONTH STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF L-000899055 IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2005)

A 2 YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF L-000899055 IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2005)

A 12-WEEK, DOSE-RANGING, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF APD356 IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2005)

DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, PARALLEL-GROUP, 16 WEEK STUDY OF 0, 400, OR 1600 MG/DAY S-2367 ADMINISTERED ORALLY ONCE-A-DAY WITH OR WITHOUT A LOW CALORIE DIET LEAD-IN IN OBESE MALES AND FEMALES
PRINCIPAL INVESTIGATOR (2005)

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF L-000414380 MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME
PRINCIPAL INVESTIGATOR (2004)

A 6-MONTH, RANDOMIZED STUDY TO EVALUATE THE EFFICACY OF VARIOUS NON-PHARMACOLOGIC, DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF OBESITY
PRINCIPAL INVESTIGATOR (2004)

A STUDY TO ASSESS THE SAFETY AND EFFICACY OF L-000899055 IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2004)

A DOUBLE-BLIND, RANDOMZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF MK-0557 IN COMBINATION WITH SIBUTRAMINE OR ORLISTAT IN OBESE SUBJECTS
PRINCIPAL INVESTIGATOR (2004)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF L-000753721 IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2003)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF L-000753721 IN MAINTAINING WEIGHT LOSS INDUCED BY A VERY LOW CALORIE DIET IN OBESE PATIENTS
PRINCIPAL INVESTIGATOR (2003)

A DOSE RANGE FINDING DOUBLE-BLIND, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND AND EFFICACY OF L-753721 IN OBESE SUBJECTS
PRINCIPAL INVESTIGATOR (2002)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, SHORT-TERM SAFETY AND EFFICACY STUDY OF TWO DOSES OF AXOKINE IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS - EXTENSION
PRINCIPAL INVESTIGATOR (2002)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, SHORT-TERM SAFETY AND EFFICACY STUDY OF TWO DOSES OF AXOKINE IN OVERWEIGHT AND OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS
PRINCIPAL INVESTIGATOR (2002)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FIXED DOSE, MULTICENTER STUDY OF WEIGHT-REDUCING AND PREVEVENTION OF WEIGHT REGAIN EFFECTS AND SAFETY OF SR141716 IN OBESE PATIENTS WITH OR WITHOUT COMORBIDITIES
PRINCIPAL INVESTIGATOR (2001)

A PHASE III, 12 MONTH, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP, PLACEBO CONTROLLED, EFFICACY AND SAFETY STUDY OF AXOKINE IN OVERWEIGHT AND OBESE SUBJECTS WITH A 12 MONTH OPEN-LABEL EXTENSION PHASE
PRINCIPAL INVESTIGATOR (2001)

RESEARCH COMPLETED TRIALS A 52 WEEK, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY OF ORLISTAT TREATMENT IN OBESE PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH INSULIN
PRINCIPAL INVESTIGATOR (1998)

L-MARC HOME PAGE